Pfizer
Europe’s neurologists unfamiliar with emerging Alzheimer’s drugs
November 17, 2010Research and Development, Sales and Marketing Alzheimer's, Aricept, Decision Resources, Europe, Pfizer
A survey of neurologists in Europe has shown only a minority are aware of late stage drugs being developed to …
Pfizer’s John Proctor moves to Quintiles
November 15, 2010Sales and Marketing John Proctor, Pfizer, Quintiles, UK, appointment, sales and marketing
Quintiles has appointed the former head of Pfizer Health Solutions to lead its own Health Management Solutions (HMS) business. As …
Digital Pharma: Pfizer and Boehringer’s online COPD awareness
November 12, 2010Medical Communications Boehringer Ingelheim, COPD, Digital Pharma blog, Managing COPD, NICE, Pfizer, Spiriva, chronic obstructive pulmonary disease
Pfizer and Boehringer Ingelheim have launched an online campaign to publicise the latest NICE guidelines on COPD to healthcare professionals …
Pfizer enters drug repositioning collaboration with Biovista
November 11, 2010Research and Development Biovista, FDA, Neurontin, Pfizer, Pfizer Indications Discovery Unit, drug repositioning, viagra
Pfizer has signed a pilot research agreement with drug repositioning specialist Biovista. The aim of the collaboration is to identify …
Pfizer and Boehringer pilot COPD campaign
November 9, 2010Medical Communications Boehringer Ingelheim, COPD, Pfizer, Salford, chronic bronchitis, chronic obstructive pulmonary disease, emphysema
Pfizer and Boehringer Ingelheim have mobilised a soap opera star, painted rugby players and a special ‘breathing bus’ for a …
Late stage trial boost for Pfizer’s arthritis drug tasocitinib
November 8, 2010JAK inhibitors, Pfizer, arthritis, tasocitinib
Pfizer’s rheumatoid arthritis treatment tasocitinib has met its two of its three primary endpoints in a phase III trial. Primary …
Pfizer Q3 profits hit hard
November 3, 2010Sales and Marketing Liptior sales, Pfizer, Pfzier Q3 results, Wyeth
The integration of Wyeth into Pfizer continues to drive its revenue growth, but at a cost – charges from the …
Pfizer pulls more Lipitor over odour problem
November 2, 2010Manufacturing and Production Lipitor, Lipitor recall, Pfizer, manufacturing compliance, recalls
Pfizer has widened its Lipitor recall after yet another incident in which consumers reported a musty smell emanating from bottles …
Pfizer to seek US approval for crizotinib next year
November 1, 2010Research and Development, Sales and Marketing FDA submission, NSCLC, Pfizer, crizotinib, lung cancer, non-small cell lung cancer
Pfizer will submit its lung cancer candidate crizotinib to the FDA for US approval in the first half of next …
NICE refuses cancer drugs Arzerra, Torisel and Levact
October 27, 2010Sales and Marketing Arzerra, GSK, NICE, Napp Pharmaceuticals, Pfizer, Torisel, Treanda, cancer drugs
NICE has refused to recommend a trio of cancer drugs for NHS use – but in two cases says this …
Two thirds of pharma companies face ‘strategic crisis’
October 25, 2010Research and Development, Sales and Marketing Novartis, Pfizer, Roland Berger, generics, pharma research, pharma sales
The pharma industry is moving away from traditional in-house innovation and toward a more diversified business model, but will encounter …
Digital Pharma: Pfizer, Enbrel and UK Google Adwords
October 22, 2010Medical Communications ABPI Code of Practice, Digital Pharma blog, Enbrel, Google Adwards, PMCPA, Pfizer, pharma SEO
Pfizer is using Google Adwords in the UK to promote an online eCongress for healthcare professionals interested in its arthritis …
Pfizer recalls Lipitor tablets because of ‘musty’ smell
October 22, 2010Manufacturing and Production Lipitor, Pfizer, pharma recalls, product recalls
Pfizer has recalled 191,000 bottles of its cholesterol drug Lipitor in the US after customers complained of an unusual, musty …
Pfizer extends portfolio with Brazilian generics deal
October 21, 2010Brazil, IMS Health, Pfizer, em, emerging pharma marketings
Pfizer is partnering with leading Brazilian generics firm Laboratorio Teuto Brasileiro to develop and commercialise a number of generic products …
Apixaban trial for ACS abandoned
October 20, 2010Sales and Marketing ACS, BMS, Pfizer, apixaban
Pfizer and Bristol-Myers Squibb have halted a trial of their heart drug apixaban after signs of increased risk of …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
